Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Quest Diagnostics's Revenue for the
three
months ended in Mar. 2026 was €2,504 Mil. Quest Diagnostics's average Accounts Receivable for the
three
months ended in Mar. 2026 was €1,288 Mil.
Hence, Quest Diagnostics's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.94.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Quest Diagnostics Receivables Turnover Related Terms
Quest Diagnostics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Quest Diagnostics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:QDI vs LH, MTD, GH: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Quest Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (FRA:QDI) has a Receivables Turnover of 1.94 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Quest Diagnostics and its competitors. According to the industry distribution chart, Quest Diagnostics ranks #51 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 25.2%.
Is Quest Diagnostics' Receivables Turnover too high?
Quest Diagnostics' current Receivables Turnover is 1.94. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Quest Diagnostics' value of 1.94 is 63.9% below this industry median. Based on the distribution chart, Quest Diagnostics ranks #51 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Quest Diagnostics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Receivables Turnover compare to LH and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Quest Diagnostics ranks #51 out of 202 companies for Receivables Turnover. This puts Quest Diagnostics in the upper half of its industry. The industry median Receivables Turnover is 5.38. Quest Diagnostics' value of 1.94 is 63.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Diagnostics's current Receivables Turnover of 1.94 is 63.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Quest Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Diagnostics's current Receivables Turnover is 1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (FRA:QDI) is currently considered Fairly Valued. The stock's GF Value™ is €166.27, compared to a current price of €181.10 — trading 8.9% above its estimated fair value. The current Receivables Turnover is 1.94 and 63.9% below the Medical Diagnostics & Research industry median of 5.38. Quest Diagnostics' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Quest Diagnostics (FRA:QDI), the current Receivables Turnover is 1.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Quest Diagnostics (FRA:QDI) Overvalued in 2026?
Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued.
The current stock price of €181.10 is trading 8.9% above its estimated GF Value™ of €166.27.
GuruFocus considers Quest Diagnostics to be Fairly Valued.
Key valuation signals for FRA:QDI:
Receivables Turnover: 1.94
GF Value™: €166.27 vs. price of €181.10 (8.9% above fair value)
Industry Position: 63.9% below the Medical Diagnostics & Research median (#51 of 202)
No single metric tells the full story. See the FRA:QDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
78GF Score
Get the complete analysis for FRA:QDI
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QDI has been successfully added to your 
